Can Selumetinib make advanced thyroid cancer sensitive to radioactive iodine therapy again?
| ISRCTN | ISRCTN17468602 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17468602 |
| EudraCT/CTIS number | 2015-002269-47 |
| Secondary identifying numbers | 19937 |
- Submission date
- 02/12/2015
- Registration date
- 02/12/2015
- Last edited
- 03/11/2021
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English Summary
Contact information
Mrs Jayne Swain
Public
Public
University of Leeds
Clinical Trials Research Unit (CTRU)
Woodhouse Lane
Leeds
LS2 9JT
United Kingdom
| Phone | 0113 343 4108 |
|---|---|
| j.swain@leeds.ac.uk |
Study information
| Study design | Non-randomised study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | SEL-I-METRY: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy |
| Study acronym | SEL-I-METRY |
| Study hypothesis | The aim of this study is to determine the proportion of patients for whom treatment with Selumetinib increases the amount of radioactive iodine taken up by the previously iodine-refractory thyroid cancers following a short course (4 weeks) of the drug. |
| Ethics approval(s) | East Midlands – Leicester South Research Ethics Committee, 02/12/2015, ref: 15/EM/0455 |
| Condition | Thyroid cancer |
| Intervention | Participants will receive an initial I-123 SPECT/CT scan (under rhTSH stimulation) to determine baseline iodine uptake in thyroid cancer lesions. Participants will then receive Selumetinib in a tablet form, which they are to take home and administer according to the dosing schedule (150mg/day, therefore 6 x 25mg tablets, 3 twice per day). Participants will then undergo another I-123 SPECT/CT after this 28-day period to determine if the iodine uptake in their thyroid cancer lesions has increased. If iodine uptake has increased sufficiently, participants will be referred for further I-131 therapy. Participants will be asked to continue taking Selumetinib from the time that they have the second I-123 scan to the time they receive their I-131. Participants who do not go on the receive I-131 therapy may stop Selumetinib treatment. The total duration of the treatment will depend on the elapsed time between the second I-123 SPECT/ CT scan, the decision about I-131 therapy being made, and the I-131 therapy being received. The minimum duration of Selumetinib therapy is approximately 28 days. The maximum may be longer (up to 50 days). Participants who do not go on to receive I-131 will have a single follow-up appointment 30 days after the final dose of Selumetinib. Participants who do go on to receive I-131 will be followed up three-monthly for one year, and then six-monthly until the end of the trial. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Selumetinib |
| Primary outcome measure | Progression-free survival is determined at 12 months. |
| Secondary outcome measures | 1. Safety is determined based on the occurrence of SAEs, SARs and SUSARs at 48 months 2. Toxicity is determined by the total number of adverse reactions, as graded by CTCAE V4.0, as identified in routine clinical assessments at each centre at 48 months 3. Radiological response rate for patients receiving radioiodine therapy is recorded at 48 months using ongoing CT scans (every 3 months for the first 6 months and then every 6 months thereafter) 4. Overall survival is determined from medical records at 48 months 5. Sufficient iodine uptake is assessed centrally using pre-defined criteria (an increase of 30% from baseline in participants who demonstrated baseline radioiodine uptake, or an increase of any level for participants who have no baseline radioiodine uptake) on an ongoing basis, with a report being collated at 48 months |
| Overall study start date | 01/02/2015 |
| Overall study end date | 05/11/2020 |
| Reason abandoned (if study stopped) | Slow recruitment and a lower than expected number of patients achieving increased iodine uptake after Selumetinib. |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 60; UK Sample Size: 60 |
| Total final enrolment | 30 |
| Participant inclusion criteria | Current participant inclusion criteria as of 03/11/2021: 1. Diagnosed with locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hürthle cell, or poorly differentiated carcinoma) with at least one measurable lesion as measured by computed tomography (CT) or magnetic resonance imaging (MRI) 2. Participants must have iodine refractory disease, defined below: 2.1. One or more measurable lesions that do not demonstrate iodine uptake on a previous radioiodine scan (diagnostic uptake or post therapy) OR 2.2. One or more measurable lesions that have progressed by RECIST 1.1 criteria within 12 months of I131 therapy, despite demonstrable radioiodine avidity at the time of that treatment 3. Participants must have radiological progression by RECIST 1.1 criteria within the prior 12 months 4. Measurable disease by RECIST 1.1 criteria. Baseline scan must be completed within 4 weeks prior to the start of treatment. 5. ECOG Performance Status = 1 and able to tolerate radioiodine therapy 6. Life expectancy of at least 12 weeks 7. Required laboratory values within 14 days of day 1 of treatment: 7.1. Adequate thyroidstimulating hormone (TSH) suppression < 0.5 mU/L 7.2. Creatinine clearance >50 ml/min, 7.3. Absolute Neutrophil Count =1.5x109/L (1500 per mm3) 7.4. Platelets =100x109/L (100,000 per mm3) 7.5. Haemoglobin >9.0 g/dL 7.6. Serum bilirubin =1.5 x upper limit of normal (ULN) 7.7. Patients with no liver metastasis must have AST or ALT = 2.5 x ULN 7.8. Patients with liver metastasis must have AST or ALT = 5 x ULN. If patients have AST or ALT > 3.5 x ULN and = 5 x ULN they must have an ALP= 6 x ULN 8. Patient’s with Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of haemolysis or hepatic pathology) will be eligible. 9. Able to give informed consent and willing to follow trial protocol. 10. Aged over 18 11. Female participants of childbearing potential must have a negative pregnancy test within 24 hours prior to starting therapy and agree to use dual methods of contraception for the duration of the trial and 6 months after completing treatment. Male participants must agree to use a barrier method of contraception for the duration of the trial and 4 months after completing treatment, if sexually active with a female of childbearing potential. Previous participant inclusion criteria: 1. Diagnosed with locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hürthle cell, or poorly differentiated carcinoma) with at least one measurable lesion as measured by computed tomography (CT) or magnetic resonance imaging (MRI) 2. Participants must have iodine refractory disease, defined below: 2.1. One or more measurable lesions that do not demonstrate iodine uptake on a previous radioiodine scan (diagnostic uptake or post therapy) OR 2.2. One or more measurable lesions that have progressed by RECIST 1.1 criteria within 12 months of I131 therapy, despite demonstrable radioiodine avidity at the time of that treatment 3. Participants must have radiological progression by RECIST 1.1 criteria within the prior 12 months 4. Measurable disease by RECIST 1.1 criteria. 5. ECOG Performance Status = 1 and able to tolerate radioiodine therapy 6. Life expectancy of at least 12 weeks 7. Required laboratory values within 14 days of day 1 of treatment: 7.1. Adequate thyroidstimulating hormone (TSH) suppression < 0.5 mU/L 7.2. Creatinine clearance >50 ml/min, 7.3. Absolute Neutrophil Count =1.5x109/L (1500 per mm3) 7.4. Platelets =100x109/L (100,000 per mm3) 7.5. Haemoglobin >9.0 g/dL 7.6. Serum bilirubin =1.5 x upper limit of normal (ULN) 7.7. Patients with no liver metastasis must have AST or ALT = 2.5 x ULN 7.8. Patients with liver metastasis must have AST or ALT = 5 x ULN. If patients have AST or ALT > 3.5 x ULN and = 5 x ULN they must have an ALP= 6 x ULN 8. Patient’s with Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of haemolysis or hepatic pathology) will be eligible. 9. Able to give informed consent and willing to follow trial protocol. 10. Aged over 18 11. Female participants of childbearing potential must have a negative pregnancy test within 24 hours prior to starting therapy and agree to use dual methods of contraception for the duration of the trial and 6 months after completing treatment. Male participants must agree to use a barrier method of contraception for the duration of the trial and 4 months after completing treatment, if sexually active with a female of childbearing potential. |
| Participant exclusion criteria | Current participant exclusion criteria as of 03/11/2021: 1. Foci of anaplastic thyroid cancer identified on histology 2. Able to receive curative surgery or radiation therapy 3. Major surgery with the exception of surgical placement for vascular access, open biopsy, or significant traumatic injury = 30 days prior to registration 4. Previous or concurrent cancer distinct in primary site or histology from thyroid cancer within previous 5 years, except for cervical cancer in situ, treated basal cell carcinoma, squamous cell carcinoma of the skin or superficial bladder tumour 5. Have received or are receiving an IMP or other systemic anticancer treatment within 4 weeks prior to the first dose of study treatment (6 weeks for nitrosoureas, mitomycin, and suramin), or within a period during which the IMP or anticancer treatment has not been cleared from the body (e.g. a period of 5 ‘halflives’), whichever is the most appropriate and as judged by the investigator 6. Any unresolved toxicity =CTCAE Grade 2 from previous anticancer therapy, except for alopecia 7. Prior exposure to Tyrosine Kinase, MEK, RAS or RAF inhibitors 8. Known or suspected allergy to Selumentinib or hypersensitivity to Selumetinib or any excipient agents or history of allergic reactions attributed to compounds of similar chemical or biologic composition to Selumetinib 9. Known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic, has been treated with surgery and / or radiation, and has been stable without requiring corticosteroids nor anticonvulsant medications for at least 4 weeks prior to the first dose of study medication 10. Requiring medication with high iodine content (e.g. amiodarone) 11. Participants who have had a iodine contrast enhanced CT scan in previous 2 months 12. Ophthalmological conditions as follows: 12.1 Intra-ocular pressure >21 mmHg, or uncontrolled glaucoma (irrespective of intra-ocular pressure) 12.2 Current or past history of retinal pigment epithelial detachment (REPD)/central serous retinopathy or retinal vein occlusion 13. Any of the following cardiac conditions: 13.1 Uncontrolled hypertension (BP >150/95 mmHg despite medical therapy) 13.2 Acute coronary syndrome within 6 months prior to starting treatment 13.3 Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical therapy) 13.4 Symptomatic heart failure (NYHA grade II-IV), prior or current cardiomyopathy, or severe vascular disease 13.5 Prior or current cardiomyopathy including but not limited to the following: 13.5.1 known hypertrophic cardiomyopathy 13.5.2 known arrhythmogenic right ventricular cardiomyopathy 13.6 Severe valvular heart disease 13.7 Left ventricular ejection fraction <55% measured by echocardiography 13.8 Atrial fibrillation with a ventricular rate >100 bpm on ECG at rest 13.9 QTcF >450ms or other factors that increase the risk of QT prolongation 14. Participants known to be infected with human immunodeficiency virus (HIV) or hepatitis B Previous participant exclusion criteria: 1. Foci of anaplastic thyroid cancer identified on histology 2. Able to receive curative surgery or radiation therapy 3. Major surgery with the exception of surgical placement for vascular access, open biopsy, or significant traumatic injury = 30 days prior to registration 4. Previous or concurrent cancer distinct in primary site or histology from thyroid cancer within previous 5 years, except for cervical cancer in situ, treated basal cell carcinoma, squamous cell carcinoma of the skin or superficial bladder tumour 5. Have received or are receiving an IMP or other systemic anticancer treatment within 4 weeks prior to the first dose of study treatment (6 weeks for nitrosoureas, mitomycin, and suramin), or within a period during which the IMP or anticancer treatment has not been cleared from the body (e.g. a period of 5 ‘halflives’), whichever is the most appropriate and as judged by the investigator 6. Any unresolved toxicity =CTCAE Grade 2 from previous anticancer therapy, except for alopecia 7. Prior exposure to Tyrosine Kinase, MEK, RAS or RAF inhibitors 8. Known or suspected allergy to Selumentinib or hypersensitivity to Selumetinib or any excipient agents or history of allergic reactions attributed to compounds of similar chemical or biologic composition to Selumetinib 9. Known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic, has been treated with surgery and / or radiation, and has been stable without requiring corticosteroids nor anticonvulsant medications for at least 4 weeks prior to the first dose of study medication 10. Requiring medication with high iodine content (e.g. amiodarone) 11. Participants who have had a iIodine contrast enhanced CT scan in previous 2 months |
| Recruitment start date | 01/09/2016 |
| Recruitment end date | 31/08/2019 |
Locations
Countries of recruitment
- England
- Scotland
- United Kingdom
Study participating centres
Bristol Haematology and Oncology Centre
Horfield Road
Bristol
BS2 8ED
United Kingdom
Bristol
BS2 8ED
United Kingdom
The Christie
Wilmslow Road
Manchester
M20 4BX
United Kingdom
Manchester
M20 4BX
United Kingdom
Churchill Hospital
Old Road
Oxford
OX3 7LE
United Kingdom
Oxford
OX3 7LE
United Kingdom
The Royal Marsden
203 Fulham Road
Chelsea
London
SW3 6JJ
United Kingdom
Chelsea
London
SW3 6JJ
United Kingdom
University Hospital Southampton
Tremona Road
Southampton
SO16 6YD
United Kingdom
Southampton
SO16 6YD
United Kingdom
Royal Surrey County Hospital
Egerton Road
Guildford
GU2 7XX
United Kingdom
Guildford
GU2 7XX
United Kingdom
The Beatson West of Scotland Cancer Centre
1053 Great Western Road
Glasgow
G12 0YN
United Kingdom
Glasgow
G12 0YN
United Kingdom
Nottingham City Hospital
Nottingham
NG5 1PB
United Kingdom
NG5 1PB
United Kingdom
Sponsor information
Sheffield Teaching Hospitals NHS Trust
Hospital/treatment centre
Hospital/treatment centre
Royal Hallamshire Hospital
Glossop Road
Sheffield
S10 2JF
England
United Kingdom
"ROR" |
https://ror.org/018hjpz25 |
|---|
Funders
Funder type
Charity
Cancer Research UK
Private sector organisation / Other non-profit organizations
Private sector organisation / Other non-profit organizations
- Alternative name(s)
- CR_UK, Cancer Research UK - London, CRUK
- Location
- United Kingdom
AstraZeneca
Government organisation / For-profit companies (industry)
Government organisation / For-profit companies (industry)
- Alternative name(s)
- AstraZeneca PLC, Pearl Therapeutics
- Location
- United Kingdom
Senofi-Genzyme
No information available
Results and Publications
| Intention to publish date | 05/11/2021 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Intended publication of a study protocol and the study results upon completion of data analysis after the end of the trial. |
| IPD sharing plan | Any requests for trial data will be reviewed by the trial management group in the first instance. Only requests that have a methodologically sound proposal and whose proposed use of the data has been approved by the independent trial steering committee will be considered. Proposals should be directed to the corresponding author in the first instance; to gain access, data requestors will need to sign a data access agreement. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | protocol | 14/06/2019 | 08/12/2020 | Yes | No |
| Basic results | version 1.0 | 03/11/2021 | 03/11/2021 | No | No |
| HRA research summary | 28/06/2023 | No | No |
Additional files
Editorial Notes
03/11/2021: The Trial Status has been updated to "Stopped" and the following changes have been made:
1. The basic results of this trial have been uploaded as an additional file.
2. The total final enrolment number has been added.
3. The individual participant data (IPD) sharing statement has been added.
4. The participant inclusion criteria have been updated.
5. The participant exclusion criteria have been updated.
01/03/2021: The following changes have been made:
1. The overall trial end date has been changed from 18/01/2020 to 05/11/2020.
2. The intention to publish date has been changed from 31/07/2020 to 05/11/2021.
08/12/2020: Publication reference added.
02/04/2019: The condition has been changed from "Topic: Cancer; Subtopic: Head and Neck Cancer; Disease: Head and Neck" to "Thyroid cancer" following a request from the NIHR.
21/03/2019: The Beatson West of Scotland Cancer Centre and Nottingham City Hospital were added as trial participating centres
14/09/2018: The following changes have been made to the trial record:
1. The recruitment end date was changed from 18/07/2018 to 31/08/2019
2. University of Leeds was removed as a trial participating centre
3. Bristol Haematology and Oncology Centre, The Christie, Churchill Hospital, The Royal Marsden, University Hospital Southampton and Royal Surrey County Hospital were added as trial participating centres
4. The study contact was changed from Sarah Flynn to Jayne Swain
5. Senofi-Genzyme was added as a funder
19/05/2017: Cancer Help UK lay summary link added to plain English summary field
10/04/2017: Internal review.
01/08/2016: The recruitment start date has been updated from 01/06/2016 to 01/09/2016.
06/04/2016: The recruitment start date was changed from 18/01/2016 to 01/06/2016.
